Currently, the company’s main market for drug testing is in North America. In the face of emerging new drugs, the company has set up an antigen R&D subsidiary in Canada, which responds to the market synchronously with the antibody production subsidiary in China, develops the latest drug detection biological raw materials in a timely manner, and continuously iterates products and expands product lines. The company has a number of international certifications such as NMPA, FDA, CE, MDL, etc., and its brand effect is continuously strengthened. Related products have been evaluated by professional laboratories in Australia and Canada, and their performance is in the forefront of the industry. In terms of the detection of infectious diseases, the company has passed the highest CE List A certification for HIV and hepatitis C detection kits due to its efficient R&D capabilities and high-quality quality management system; the company has received funding from the Bill & Melinda Gates Foundation for the World Health Organization pre-certification of malaria detection kits. The company’s malaria (Pf/Pan) and malaria (Pf) detection kits have passed the fifth and seventh rounds of WHO evaluation respectively, and are expected to become the first Chinese enterprise to obtain the WHO pre-certification, which will promote the internationalization of China’s in vitro diagnostic industry.